CEPI Leads the Charge in Lassa Fever Vaccine Development
CEPI's Significant Investment in Lassa Fever Research
The Coalition for Epidemic Preparedness Innovations (CEPI), a global health coalition, has disclosed an impressive investment of over $250 million in Lassa fever studies since 2017. The primary objective of this funding is to develop a vaccine for this serious viral disease.
Details from the Announcement
This substantial investment was revealed by Gabrielle Breugelmans, Director of Epidemiology and Data Science at CEPI, during the inauguration of the Enable 1.5 cohort study in Abuja on Wednesday. Breugelmans emphasized CEPI's comprehensive financial commitment over the years, underscoring the urgency of finding a solution to Lassa fever.
- Lassa fever is endemic in West Africa.
- CEPI aims to enhance vaccine development efforts.
- The funding will facilitate crucial research projects.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.